We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

42 hedge funds and large institutions have $176M invested in Y-mAbs Therapeutics in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

14% more funds holding

Funds holding: 37 → 42 (+5)

2.98% more ownership

Funds ownership: 22.42% → 25.41% (+3%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

14% less capital invested

Capital invested by funds: $205M → $176M (-$29.7M)

Holders
42
Holders Change
+5
Holders Change %
+13.51%
% of All Funds
0.94%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
17
Increased
10
Reduced
10
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.09M
2
BlackRock
BlackRock
New York
+$7.51M
3
AllianceBernstein
AllianceBernstein
Tennessee
+$5.31M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.95M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.79M

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$3.32M
2
AG
Artal Group
Luxembourg
-$2.3M
3
Goldman Sachs
Goldman Sachs
New York
-$1.69M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.33M
5
BBA
Baker Bros. Advisors
New York
-$1.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$210K +$237K +10,339 New
Deutsche Bank
27
Deutsche Bank
Germany
$191K +$217K +9,452 New
TAM
28
Tiverton Asset Management
Delaware
$170K -$109K -4,742 -36%
Bank of America
29
Bank of America
North Carolina
$122K +$134K +5,838 +3,057%
AIG
30
American International Group
New York
$93K +$105K +4,585 New
FCM
31
Flinton Capital Management
Pennsylvania
$85K -$108K -4,692 -53%
UBS Group
32
UBS Group
Switzerland
$75K +$84.4K +3,674 New
TAM
33
Tyers Asset Management
Texas
$70K -$88.7K -3,864 -53%
Wells Fargo
34
Wells Fargo
California
$70K +$82.7K +3,600 New
NA
35
Neuburgh Advisers
California
$55K -$69.7K -3,036 -53%
MCIM
36
Meadow Creek Investment Management
Georgia
$40K -$50.7K -2,208 -53%
SO
37
STRS Ohio
Ohio
$38K +$43.6K +1,900 New
Citigroup
38
Citigroup
New York
$37K +$42.1K +1,834 New
Legal & General Group
39
Legal & General Group
United Kingdom
$22K +$24.7K +1,074 New
AIP
40
Ameritas Investment Partners
Nebraska
$12K +$13.2K +575 New
CCA
41
Catalyst Capital Advisors
New York
$10K – – –
TRCT
42
Tower Research Capital (TRC)
New York
$7K +$8.2K +357 New
FCM
43
Farallon Capital Management
California
– -$3.32M -125,000 Closed
Alyeska Investment Group
44
Alyeska Investment Group
Illinois
– -$1.33M -50,000 Closed
Man Group
45
Man Group
United Kingdom
– -$1.06M -40,000 Closed
DIM
46
DC Investments Management
Virginia
– -$664K -25,000 Closed
WRF
47
Waddell & Reed Financial
Kansas
– -$664K -25,000 Closed
PVI
48
Pura Vida Investments
New York
– -$594K -22,350 Closed
Norges Bank
49
Norges Bank
Norway
– -$398K -15,000 Closed
GCP
50
GSA Capital Partners
United Kingdom
– -$266K -10,000 Closed
1
2
3

YMAB Hedge Fund Activity: Q4 2018 in Review

42 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2018, worth a combined $176M — down 14% from $205M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new YMAB positions and 12 closed out — a net gain of 5 holders — while 10 added to existing stakes and 10 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $9.09M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $3.32M sold.

  • 42 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2018, up from 37 in Q3 2018.
  • Funds reported $176M of Y-mAbs Therapeutics stock for Q4 2018, down 14% quarter-over-quarter.
  • 17 funds opened new Y-mAbs Therapeutics positions in Q4 2018 and 12 closed out, a net change of +5 holders.
  • The largest Y-mAbs Therapeutics buyer in Q4 2018 was Fidelity Investments, an estimated $9.09M added.
  • The largest Y-mAbs Therapeutics seller in Q4 2018 was Farallon Capital Management, an estimated $3.32M sold.

Based on aggregated 13F filings for Q4 2018.